Podcasts about GU

DESCRIPCIÓN: La mente inventa, la conciencia observa: salir del miedo y volver al presente. En este episodio exploro cómo la mente crea escenarios irreales basados en memorias, miedos y condicionamientos, y cómo estos pensamientos automáticos pueden desconectarnos del presente.Guío al oyente a reconocer la diferencia entre la mente que inventa y la conciencia que observa, enseñando cómo regresar al estado de presencia donde existe la verdadera claridad y la paz interior.

La guitarrista i cantautora, nascuda a Bilbao i ve

El Tribunal Supremo ha declarado culpable al fiscal general del Estado, Álvaro García Ortiz, por un delito de revelación de secretos. La condena le inhabilita para el cargo por dos años, le impone una multa de 7.200 euros y le obliga a indemnizar con 10.000 euros a Alberto González Amador, pareja de Isabel Díaz Ayuso. El tribunal condena al fiscal general a pesar de la existencia de pruebas directas, y a pesar de los cinco testimonios de cinco periodistas diferentes que negaron que García Ortiz les filtrase el correo electrónico en el que el abogado de González Amador admitía haber cometido un delito de fraude a Hacienda. Con Iñigo Sáenz de Ugarte y Alberto Pozas, periodistas de elDiario.es que han cubierto este proceso, analizamos las claves de una condena histórica, a la espera de conocer los razonamientos del Tribunal Supremo en la sentencia. *** Envíanos una nota de voz por Whatsapp contándonos alguna historia que conozcas o algún sonido que tengas cerca y que te llame la atención. Lo importante es que sea algo que tenga que ver contigo. Guárdanos en la agenda como “Un tema Al día”. El número es el 699 518 743See omnystudio.com/listener for privacy information.

Price Action Trader - Curso en Vivo | 24 al 26 de Noviembre 2025. Mas información sobre el curso Aquí!

Slovenský futbalový tréner Adrián Guľa otvorene prehovoril o svojej prvej sezóne v lotyšskom tíme FC Riga, kde hneď v úvodnom ročníku doviedol klub po štyroch rokoch k vytúženému majstrovskému titulu. V exkluzívnom rozhovore v podcaste Striedame! na ŠPORT.sk odhalil nielen detaily zo zákulisia úspešnej sezóny, ale aj momenty, keď musel zvažovať svoj odchod.Adrián Guľa neskrýva, že úvod v Rige bol dramatický. Po prvých štyroch zápasoch mal bilanciu 1 výhra, 2 remízy, 1 prehra. „Ešte som nebol ani vybalený. Býval som na akadémii,” priznáva otvorene tréner, ktorý do projektu išiel s jasným poslaním - vyhrať titul alebo odísť.Situácia bola natoľko vyhrotená, že s manažmentom klubu si museli nanovo nastaviť pravidlá spolupráce. „Dostali sme to na hranu a z nej sme sa potom odrazili do pozitívna, ale naozaj to bolo na hrane,” vysvetľuje 50-ročný kouč, ktorý v kluboch ako Plzeň či Dunajská Streda nebol zvyknutý na takýto typ riadenia.Po zvládnutí úvodnej krízy prišla nevídaná dominancia. Riga zaznamenala 15 víťazstiev po sebe a celkovo 31 zápasov bez prehry. Ako sa to podarilo? Adrián Guľa odhalil svoju filozofiu budovania tímu: „Vnímam hráčov ako ľudí, ako partnerov. Disciplína, charakter a dobrá mentalita plus silný team spirit.”Zaujímavou súčasťou rozhovoru je pohľad do fungovania klubu s hráčmi z 10 rôznych národností - od Peru cez Ghanu až po Ukrajinu. „Medzi hráčmi sa rozpráva minimálne tromi jazykmi,” opisuje Adrián Guľa prostredie, kde angličtina, španielčina aj francúzština tvoria každodenný komunikačný mix.Šokujúcim odhalením je finančné nastavenie klubu: „Pätnásť víťazstiev za sebou a jednoducho nula. Čistá nula.” Prémie boli viazané výlučne na konečný výsledok - zisk majstrovského titulu.Tréner sa venoval aj neúspešnému pokusu prebojovať sa do skupinovej fázy európskych pohárov, kde Rigu vyradila pražská Sparta. Zároveň načrtol víziu klubu do budúcnosti a hovoril aj o tom, čo by ho presvedčilo na odchod z Lotyšska.V rozhovore Adrián Guľa neskrýval ani emócie po nedávnom vysokom debakli slovenskej reprezentácie, v ktorej s hráčmi má osobné vzťahy z predchádzajúcich pôsobení.Celý rozhovor prináša úprimný pohľad na život trénera v zahraničí, fungovanie moderného futbalového klubu pod vedením ruského investora Sergeja Lomakina a detaily z prostredia lotyšskej ligy, o ktorej sa na Slovensku vie len málo.

Bítið á Bylgjunni með Heimi, Lilju og Ómari.   Bogi Ragnarsson, félagsfræðingur og kennari, ræddi við okkur um unglingadrykkju og frétt Ríkissjónvarpsins um málið.   Símatími.   Sigurjón Kjartansson og Jón Gnarr fóru yfir fréttir vikunnar.   Kristín Ása Brynjarsdóttir og Ragnar Másson, eigendur og stofnendur Memore, kíktu til okkar í spjall. Unnar Freyr Jónsson frá Kornax og Kolbrún Haraldsdóttir frá GÓU mættu með fullt af smákökum.

Föstudagsgestur Mannlega þáttarins í þetta sinn var Arnór Pálmi Arnarson leikstjóri. Hann byrjaði mjög ungur að leikstýra kvikmyndaefni, sjónvarpsþáttaraðirnar Hæ gosi, Ligeglad, Ráðherrann, áramótaskaupið og fleiri. Og svo nú, ný spennuþáttaröð, Heimaey, sem hóf göngu sína hjá Sjónvarpi Símans í gær. Við ferðuðumst um í tíma og rúmi með Arnóri Pálma og forvitnuðumst auðvitað um þessa nýju þætti sem gerast, eins og nafnið gefur til kynna, í Vestmannaeyjum, en reyndar líka í Portúgal. Svo var það matarspjallið með Sigurlaugu Margréti. Í dag ræddum við með henni um matsárni, vonir og væntingar, þegar kemur að því til dæmis að fara út að borða, í samanburði til dæmis við það að elda heima. Tónlist í þættinum i dag: Bella símamær / Björk Guðmundsdóttir og Tríó Guðmundar Ingólfssonar (Marc Fontenoy, texti Guðmundur Guðmundsson) Ég veit þú kemur / Ási í Bæ (Oddgeir Kristjánsson, texti Ási í Bæ) Golden Slumbers / Carry that Weight - The Beatles (Lennon & McCartney) UMSJÓN: GUÐRÚN GUNNARSDÓTTIR OG GUNNAR HANSSON

Slovenský futbalový tréner Adrián Guľa otvorene prehovoril o svojej prvej sezóne v lotyšskom tíme FC Riga, kde hneď v úvodnom ročníku doviedol klub po štyroch rokoch k vytúženému majstrovskému titulu. V exkluzívnom rozhovore v podcaste Striedame! na ŠPORT.sk odhalil nielen detaily zo zákulisia úspešnej sezóny, ale aj momenty, keď musel zvažovať svoj odchod.Adrián Guľa neskrýva, že úvod v Rige bol dramatický. Po prvých štyroch zápasoch mal bilanciu 1 výhra, 2 remízy, 1 prehra. „Ešte som nebol ani vybalený. Býval som na akadémii,” priznáva otvorene tréner, ktorý do projektu išiel s jasným poslaním - vyhrať titul alebo odísť.Situácia bola natoľko vyhrotená, že s manažmentom klubu si museli nanovo nastaviť pravidlá spolupráce. „Dostali sme to na hranu a z nej sme sa potom odrazili do pozitívna, ale naozaj to bolo na hrane,” vysvetľuje 50-ročný kouč, ktorý v kluboch ako Plzeň či Dunajská Streda nebol zvyknutý na takýto typ riadenia.Po zvládnutí úvodnej krízy prišla nevídaná dominancia. Riga zaznamenala 15 víťazstiev po sebe a celkovo 31 zápasov bez prehry. Ako sa to podarilo? Adrián Guľa odhalil svoju filozofiu budovania tímu: „Vnímam hráčov ako ľudí, ako partnerov. Disciplína, charakter a dobrá mentalita plus silný team spirit.”Zaujímavou súčasťou rozhovoru je pohľad do fungovania klubu s hráčmi z 10 rôznych národností - od Peru cez Ghanu až po Ukrajinu. „Medzi hráčmi sa rozpráva minimálne tromi jazykmi,” opisuje Adrián Guľa prostredie, kde angličtina, španielčina aj francúzština tvoria každodenný komunikačný mix.Šokujúcim odhalením je finančné nastavenie klubu: „Pätnásť víťazstiev za sebou a jednoducho nula. Čistá nula.” Prémie boli viazané výlučne na konečný výsledok - zisk majstrovského titulu.Tréner sa venoval aj neúspešnému pokusu prebojovať sa do skupinovej fázy európskych pohárov, kde Rigu vyradila pražská Sparta. Zároveň načrtol víziu klubu do budúcnosti a hovoril aj o tom, čo by ho presvedčilo na odchod z Lotyšska.V rozhovore Adrián Guľa neskrýval ani emócie po nedávnom vysokom debakli slovenskej reprezentácie, v ktorej s hráčmi má osobné vzťahy z predchádzajúcich pôsobení.Celý rozhovor prináša úprimný pohľad na život trénera v zahraničí, fungovanie moderného futbalového klubu pod vedením ruského investora Sergeja Lomakina a detaily z prostredia lotyšskej ligy, o ktorej sa na Slovensku vie len málo.

Agradece a este podcast tantas horas de entretenimiento y disfruta de episodios exclusivos como éste. ¡Apóyale en iVoox! Llega el invierno y entre muchos festivales y documentales, hoy ponemos el foco en el realizado por dos amigos: Thomas Rich y Alex Miguel a finales del pasado mes de marzo en Dolomitas. Reunión es el título de 15 minutos de acción por canales imposibles... para muchos mortales amantes del esquí y de la tabla. Luego se viene otro amigo: Juan Bazán. Guía de montaña, vehemente en sus declaraciones, hablamos sobre restricccio0nes llegado el invierno, las nuevas mediciones de tresmiles y la última asamblea de la AEGM que tiene su sede en Jaca. Escucha el episodio completo en la app de iVoox, o descubre todo el catálogo de iVoox Originals

Si hay algo en que este podcast ha sido consistente en los pasados cinco años es en tres cosas: disparates, información sin corroborar y vaticinios mach0rros. ¡Nosotros no fallamos, papeh! Se está jodiendo el Internet y continúan los ciberataques que dejaron a miles sin tuitear por horas, los drones venezolanos ya se acercan a la costa de Guánica, mientras que aseguran que Ricky Rosselló aparecía en la lista de Epstein. También conocimos al mejor gruero de la isla, celebramos que Coscu salió bien de un nuevo caso y le pedimos a la comunidad mach0rra para encontrar a la mascota que se robó nuestros corazones: Ozzy, el murciélago de Corozal. #BuscandoAOzzy ¡Esto es La Hora Mach0rra, papeh!   Dale ‘follow' a la nueva cuenta de los Mach0rros en IG: https://www.instagram.com/lahoramach0rra/   EL MEJOR PATREON DE PUERTO RICO: https://www.patreon.com/lahoramachorra   LAS MEJORES BATERÍAS Y GENERADORES: https://generatorsandmoreonline.com/    LA MEJOR TIENDA DE ROPA: (TODA MODA en CAGUAS): https://www.instagram.com/todamoda/   USA EL CÓDIGO "MACHORRA15" PARA UN 15% DE DESCUENTO EN: https://www.manscaped.com/   PARA ARBOLITOS CUSTOM DE NAVIDAD Y OTRAS ARTESANÍAS: https://www.instagram.com/pr_artisans/ INSTAGRAM: https://www.instagram.com/lahoramach0rra/ CANAL DE CLIPS: https://www.youtube.com/c/lahoramachorraclips LA MARCA DE ROPA DE VALI: https://www.resistancecompany.com/   Hosts: Alexis 'Macetaminofén' Zárraga, José Valiente & Oscar Navarro === REDES === Maceta https://www.facebook.com/TioMacetaminofen https://twitter.com/Macetaminofen https://www.instagram.com/macetaminofen/ Valiente https://www.youtube.com/user/valiente101 https://twitter.com/JoseValiente https://www.instagram.com/josevalientepr/ Oscar https://linktr.ee/oscarnavarropr     

Según la versión oficial, la Transición española fue un proceso pacífico y ejemplar. Y fue posible, además, por la “generosidad” de Juan Carlos I quien, pudiendo elegir perpetuarse al frente de un régimen totalitario, optó por “concederle” al pueblo español todos sus derechos democráticos. La realidad de lo que ocurrió en aquellos años no fue así de idílica, de pacífica y ni tampoco así de generosa. La Transición española fue un proceso convulso y violento en el que murieron más de 700 personas fruto de la represión policial, la violencia fascista y el terrorismo. Con Gumersindo Lafuente, editor de la Revista de elDiario.es recordamos cómo fue la lucha colectiva en las calles de multitud de ciudadanos y ciudadanas lo que realmente empujó a los herederos del franquismo a iniciar un proceso democratizador, y analizamos también cómo la versión edulcorada de estos hechos sigue condicionando los debates políticos y sociales de todo un país 50 años después. *** ‘La Transición: la democracia no la trajo el rey, se ganó en la calle’, la revista de elDiario.es *** Envíanos una nota de voz por Whatsapp contándonos alguna historia que conozcas o algún sonido que tengas cerca y que te llame la atención. Lo importante es que sea algo que tenga que ver contigo. Guárdanos en la agenda como “Un tema Al día”. El número es el 699 518 743See omnystudio.com/listener for privacy information.

Það er blár nóvember, þ.e.a.s. í þessum mánuði er vitundarvakning um blöðruhálskirtilskrabbamein hjá körlum. Við kynntum okkur helstu upplýsingar um það og krabbameinsfélagið Framför í þættinum í dag, en Guðmundur Páll Ásgeirsson formaður og Hólmfríður Sigurðardóttir varaformaður komu í þáttinn og sögðu okkur frá starfi félagsins, Makafélaginu Traustir makar og fleiru. Hvað tekur við þegar starfsævinni lýkur og eftirlaunaaldri er náð? Tekjumunur milli kvenna og karla helst ævina á enda og konur fá ekki bara lægri laun en karlar á vinnumarkaði heldur einnig lægri lífeyri. Á málstofu fyrr í morgun fóru sérfræðingar yfir tölulegar upplýsingar um stöðu kynjanna, þar var fjallað um lífeyriskerfið út frá jafnréttissjónarmiðum og velt upp möguleikum til að jafna leikinn. Steinunn Bragadóttir, hagfræðingur hjá ASÍ, kom í þáttinn og sagði okkur frá erindi sem hún hélt á málstofunni þar sem teknar voru saman tölur um tekjur kvenna og karla á ellilífeyrisaldri. Hrafn Úlfarsson, sérfræðingur frá Lífeyrissjóði verzlunarmanna, kom með Steinunni í þáttinn og fór yfir mun á lífeyrisgreiðslum til karla og kvenna hjá sjóðnum, hver þróunin hefur verið og framtíðarhorfur. Valdimar Þór Svavarsson ráðgjafi var svo hjá okkur í dag eins og undanfarna fimmtudaga og hélt áfram að fræða okkur um mannleg samskipti. Í síðustu viku töluðum við um narsissisma og við héldum því áfram í dag, meðal annars hvað er hægt að gera þegar kemur að samskiptum við narsissíska einstaklinga. Tónlist í þættinum i dag: Eingetið ljóð / Bjartmar Guðlaugsson (Bjartmar Guðlaugsson) I Would Run Away With You / Bambaló (Kristjana Stefánsdóttir) Landleguvalsinn / Haukur Morthens (Jónatan Ólafsson, texti Númi Þorbergsson) UMSJÓN: GUÐRÚN GUNNARSDÓTTIR OG GUNNAR HANSSON

Qui va appeler RMC aujourd'hui ? Tom Cruise, Emmanuel Macron ? Gislain de Guéret ? « Le répondeur de Pierre-Antoine Damecour » détourne le 3216 de RMC tous les jours, du lundi au vendredi, à 13h50 dans « Estelle Midi ».

Fimmtudagur 20. nóvember Reynsuboltar, friðarplan, krabbamein, gervigreind og skáldið Sigurjón Magnús tekur á móti reynsluboltum og ræðir um fréttir vikunnar og vettvang dagsins: Viðar Eggertsson leikari, Kristín Helga Gunnarsdóttir rithöfundur og Árni Guðmundsson forvarnarfulltrúi skemmta hvort öðru og okkur með spjalli um daginn og veginn. Hilmar Þór Hilmarsson prófessor ræðir friðarplan Trump við Gunnar Smára og hvort honum takist að troða því ofan í kokið á Úkraínu og Evrópu. Hannes Rúnar Hannesson varaformaður Krafts og Melkorka Matthíasson sem starfar hjá Ljósinu ræða við Ragnheiði Davíðsdóttur um sára reynslu sína af krabbameini. Stefán Atli Rúnarsson er viðskiptafræðingur, fjölmiðlatækni og eigandi ChatGPT námskeið.is þar sem hann kennir fólki að umgangast gervigreindina. Hann sagði Gunnari Smára frá sinni reynslu og sýn á þetta furðufyrirbrigði sem gervigreindin er. Kristín Ómarsdóttir skáld ræðir við Gunnar Smára um bækur sínar um langömmu sína, um skáldskapinn, tímann, tímamótin og fleira sem skemmtilegt er að spjalla um.

Les invités : Vincent BOURGON Ingénieur commercial ENGIE solutions Hydrogène Guénaële LE GARFF, directeur opérationnel de l'AREC Occitanie Table ronde animée par Boris GEORGELIN Toute l'actualité de INN'O c'est icihttps://salon-inno.fr/Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

00:00:00 : Bande-annonce Conférence Guérison & Réveil 2e édition 00:01:37 : Début de l'émission

Este es el episodio #135 de "Tradiciones Sabias", el podcast en español de la Fundación Weston A. Price. Algunos de los temas de este episodio - -Qué significa y cómo funciona el eje intestino-piel -Cómo podemos hidratar nuestra piel -Cuáles son los alimentos que mejor nutren nuestra piel -Qué productos comunes en nuestra alacena pueden ser nocivos a nuestra piel -Posibles efectos del cigarrillo, vaping y el consumo de alcohol -Rol de la piel en la lactancia y primeros días de vida Datos del invitado -  Patricia es natural de Medellín, Colombia. Durante más de 20 años ha estudiado y aplicado sus conocimientos en química orgánica, medicinas antiguas, medicina funcional y  bio regulatoria y ayurveda. Logró revertir su diabetes y ha ayudado a miles de personas a construir salud mediante programas educativos y alimenticios enfocados en la sabiduría del cuerpo humano. Contacto - Instagram: drpatriciarestrepo  Web: www.beboon.net  y www.keat.mx Recursos en español de la Fundación Weston A. Price -   Página web WAPF en Español: https://www.westonaprice.org/espanol/ Cuenta de Instagram: westonaprice_espanol Guía alimentación altamente nutritiva, saludable y placentera: 11 principios dietéticos Paquete de Materiales GRATIS: https://secure.westonaprice.org/CVWEBTEST_WESTON/cgi-bin/memberdll.dll/openpage?wrp=customer_new_infopak_es.htm  Folleto "La Leche Real", de Sally Fallon:  https://www.westonaprice.org/wp-content/uploads/La-leche-real.pdf  Música de Pixabay - Sound Gallery y SOFRA

A la sessi

Utanríkisráðherrar EES ríkjanna verða á morgun í Brussel á fundi ráðherraráðs Evrópska efnahagssvæðisins. Fundurinn er haldinn í skugga þeirrar ákvörðunar um verndarráðstafanir sem Evrópusambandið ákvað á þriðjudaginn. Björn Malmquist fréttamaður ræddi þessi mál við Þorgerði Katrínu Gunnarsdóttur utanríkisráðherra sem kom til Brussel í dag. Seðlabanki Íslands lækkaði í dagstýrivexti um 0,25 prósentustig. Anna Kristín Jónsdóttir leitaði álits Katrínar Ólafsdóttur deildarforseta viðskipta- og hagfræðideildar Háskólans í Reykjavík, á þessari ákvörðun og mögulegum afleiðingum hennar. Ráðuneytisstjóri í forsætisráðuneytinu fundaði með Sigríði Björk Guðjónsdóttur þáverandi ríkislögreglustjóra undir fjögur augu nokkrum dögum áður en hún sagði af sér embætti. Fundurinn var haldinn á heimili ráðuneytisstjórans að loknum vinnudegi. Forsætisráðherra segir ráðuneytisstjórann ekki hafa farið með nein skilaboð frá henni inn á fundinn. Freyr Gígja Gunnarsson fjallar um málið. Umsjón: Ævar Örn Jósepsson Tæknimaður: Kári Guðmundsson

Cómo generar FOMO real en inversionistas (sin mentir) — con Marcus Dantus (Startup México, ex Shark Tank México). Guía práctica para founders en Latinoamérica: tracción > discurso, due diligence sin humo, y equipos que inspiran confianza.En este episodio aprenderás:- Tácticas para crear urgencia auténtica (rondas en curso, contratos por cerrar, lanzamientos) sin exagerar.- El checklist de un inversionista: necesidad, diferenciación, equipo y banderas rojas en segundos.- Por qué la primera reunión sirve para conseguir la segunda (y cómo medir tu progreso real).- El cuello de botella en LATAM (pocas salidas) y cómo contar tu historia para atraer capital.Frase clave:“Una cosa es generar FOMO y otra es decir mentiras. Las mentiras te las cachan en la primera junta, en la segunda o en el due diligence.” — Marcus DantusCapítulos:00:00 FOMO real vs. humo (cita clave)02:30 Checklist del pitch: necesidad, diferenciación, equipo07:00 FOMO con transparencia: rondas, contratos y lanzamientos12:00 Tracción que sube la valuación16:30 Equipo multidisciplinario y banderas rojas20:00 Salidas financieras en LATAM25:00 Cierre: credibilidad = tracción + transparenciaInvitado:Marcus Dantus — Emprendedor, inversionista y Shark en Shark Tank MéxicoSígueme para más sobre startups, venture capital e innovación:LinkedIn: https://www.linkedin.com/in/jaimersb/X: https://x.com/jaimersbInstagram: https://www.instagram.com/jaimersb/#InnovacionSinBarreras #FOMO #VentureCapital #Startups #LatAm #SharkTankMexico

Authors Drs. Jessica Ross and Alissa Cooper share insights into their JCO PO article, "Clinical and Pathologic Landscapes of Delta-Like Ligand 3 and Seizure-Related Homolog Protein 6 Expression in Neuroendocrine Carcinomas"  Host Dr. Rafeh Naqash and Drs. Ross and Cooper discuss the landscape of Delta-like ligand 3 (DLL3) and seizure-related homolog protein 6 (SEZ6) across NECs from eight different primary sites. TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash, podcast editor for JCO PO and an Associate Professor at the OU Health Stephenson Cancer Center. Today, I'm excited to be joined by Dr. Jessica Ross, third-year medical oncology fellow at the Memorial Sloan Kettering Cancer Center, as well as Dr. Alissa Cooper, thoracic medical oncologist at the Dana-Farber Cancer Institute and instructor in medicine at Harvard Medical School. Both are first and last authors of the JCO Precision Oncology article entitled "Clinical and Pathologic Landscapes of Delta-like Ligand 3 and Seizure-Related Homolog Protein 6 or SEZ6 Protein Expression in Neuroendocrine Carcinomas." At the time of this recording, our guest disclosures will be linked in the transcript. Jessica and Alissa, welcome to our podcast, and thank you for joining us today. Dr. Jessica Ross: Thanks very much for having us. Dr. Alissa Cooper: Thank you. Excited to be here. Dr. Rafeh Naqash: It's interesting, a couple of days before I decided to choose this article, one of my GI oncology colleagues actually asked me two questions. He said, "Rafeh, do you know how you define DLL3 positivity? And what is the status of DLL3 positivity in GI cancers, GI neuroendocrine carcinomas?" The first thing I looked up was this JCO article from Martin Wermke. You might have seen it as well, on obrixtamig, a phase 1 study, a DLL3 bi-specific T-cell engager. And they had some definitions there, and then this article came along, and I was really excited that it kind of fell right in place of trying to understand the IHC landscape of two very interesting targets. Since we have a very broad and diverse audience, especially community oncologists, trainees, and of course academic clinicians and some people who are very interested in genomics, we'll try to make things easy to understand. So my first question for you, Jessica, is: what is DLL3 and SEZ6 and why are they important in neuroendocrine carcinomas? Dr. Jessica Ross: Yeah, good question. So, DLL3, or delta-like ligand 3, is a protein that is expressed preferentially on the tumor cell surface of neuroendocrine carcinomas as opposed to normal tissue. It is a downstream target of ASCL1, and it's involved in neuroendocrine differentiation, and it's an appealing drug target because it is preferentially expressed on tumor cell surfaces. And so, it's a protein, and there are several drugs in development targeting this protein, and then Tarlatamab is an approved bi-specific T-cell engager for the treatment of extensive-stage small cell lung cancer in the second line. SEZ6, or seizure-like homolog protein 6, is a protein also expressed on neuroendocrine carcinoma cell surface. Interestingly, so it's expressed on neuronal cells, but its exact role in neuroendocrine carcinomas and oncogenesis is actually pretty poorly understood, but it was identified as an appealing drug target because, similarly to DLL3, it's preferentially expressed on the tumor cell surface. And so this has also emerged as an appealing drug target, and there are drugs in development, including antibody-drug conjugates, targeting this protein for that reason. Dr. Alissa Cooper: Over the last 10 to 15 years or so, there's been an increasing focus on precision oncology, finding specific targets that actually drive the cancer to grow, not just within lung cancer but in multiple other primary cancers. But specifically, at least speaking from a thoracic oncology perspective, the field of non-small cell lung cancer has completely exploded over the past 15 years with the discovery of driver oncogenes and then matched targeted therapies. Within the field of neuroendocrine carcinomas, including small cell lung cancer but also other high-grade neuroendocrine carcinomas, there has not been the same sort of progress in terms of identifying targets with matched therapies. And up until recently, we've sort of been treating these neuroendocrine malignancies kind of as a monolithic disease process. And so recently, there's been sort of an explosion of research across the country and multiple laboratories, multiple people converging on the same open questions about why might patients with specific tumor biologies have different kind of responses to different therapies. And so first this came from, you know, why some patients might have a good response to chemo and immunotherapy, which is the first-line approved therapy for small cell lung cancer, and we also sort of extrapolate that to other high-grade neuroendocrine carcinomas. What's the characteristic of that tumor biology? And at the same time, what are other targets that might be identifiable? Just as Jesse was saying, they're expressed on the cell surface, they're not necessarily expressed in normal tissue. Might this be a strategy to sort of move forward and create smarter therapies for our patients and therefore move really into a personalized era for treatment for each patient? And that's really driving, I think, a lot of the synthesis of this work of not only the development of multiple new therapies, but really understanding which tumor might be the best fit for which therapy. Dr. Rafeh Naqash: Thank you for that explanation, Alissa. And as you mentioned, these are emerging targets, some more further along in the process with approved drugs, especially Tarlatamab. And obviously, DLL3 was something identified several years back, but drug development does take time, and readout for clinical trials takes time. Could you, for the sake of our audience, try to talk briefly about the excitement around Tarlatamab in small cell lung cancer, especially data that has led to the FDA approval in the last year, year and a half? Dr. Alissa Cooper: Sure. Yeah, it's really been an explosion of excitement over, as you're saying, the last couple of years, and work really led by our mentor, Charlie Rudin, had identified DLL3 as an exciting target for small cell lung cancer specifically but also potentially other high-grade neuroendocrine malignancies. Tarlatamab is a DLL3-targeting bi-specific T-cell engager, which targets DLL3 on the small cell lung cancer cells as well as CD3 on T cells. And the idea is to sort of introduce the cancer to the immune system, circumventing the need for MHC class antigen presentation, which that machinery is typically not functional in small cell lung cancer, and so really allowing for an immunomodulatory response, which had not really been possible for most patients with small cell lung cancer prior to this. Tarlatamab was tested in a phase 2 registrational trial of about 100 patients and demonstrated a response rate of 40%, which was very exciting, especially compared with other standard therapies which were available for small cell lung cancer, which are typically cytotoxic therapies. But most excitingly, more than even the response rate, I think, in our minds was the durability of response. So patients whose disease did have a response to Tarlatamab could potentially have a durable response lasting a number of months or even over a year, which had previously not ever been seen in this in the relapsed/refractory setting for these patients. I think the challenge with small cell lung cancer and other high-grade neuroendocrine malignancies is that a response to therapy might be a bit easier to achieve, but it's that durability. The patient's tumors really come roaring back quite aggressively pretty quickly. And so this was sort of the most exciting prospect is that durability of response, that long potential overall survival tail of the curve really being lifted up. And then most recently at ASCO this year, Dr. Rudin presented the phase 3 randomized controlled trial which compared Tarlatamab to physician's choice of chemotherapy in a global study. And the choice of chemotherapy did vary depending on the part of the world that the patients were enrolled in, but in general, it was a really markedly positive study for response rate, for progression-free survival, and for overall survival. Really exciting results which really cemented Tarlatamab's place as the standard second-line therapy for patients with small cell lung cancer whose disease has progressed on first-line chemo-immunotherapy. So that has been very exciting. This drug was FDA approved in May of 2024, and so has been used extensively since then. I think the adoption has been pretty widespread, at least in the US, but now in this global trial that was just presented, and there was a corresponding New England Journal paper, I think really confirms that this is something we really hopefully can offer to most of our patients. And I think, as we all know, that this therapy or other therapies like it are also being tested potentially in the first-line setting. So there was data presented with Tarlatamab incorporated into the maintenance setting, which also showed exciting results, albeit in a phase 1 trial, but longer overall survival than we're used to seeing in this patient population. And we await results of the study that is incorporating Tarlatamab into the induction phase with chemotherapy as well. So all of this is extraordinarily exciting for our patients to sort of move the needle of how many patients we can keep alive, feeling functional, feeling well, for as long as possible. Dr. Rafeh Naqash: Very exciting session at ASCO. I was luckily one of the co-chairs for the session that Dr. Rudin presented it, and I remember somebody mentioning there was more progress seen in that session for small cell lung cancer than the last 30, 35 years for small cell, very exciting space and time to be in as far as small cell lung cancer. Now going to this project, Jessica, since you're the first author and Alissa's the last, I'm assuming there was a background conversation that you had with Alissa before you embarked on this project as an idea. So could you, again, for other trainees who are interested in doing research, and it's never easy to do research as a resident and a fellow when you have certain added responsibilities. Could you give us a little bit of a background on how this started and why you wanted to look at this question? Dr. Jessica Ross: Yeah, sure. So, as with many exciting research concepts, I think a lot of them are derived from the clinic. And so I think Alissa and I both see a good number of patients with small cell, large cell lung cancer, and then high-grade neuroendocrine carcinomas. And so I think this was really born out of a basic conversation of we have these drugs in development targeting these two proteins, DLL3 and SEZ6, but really what is the landscape of cancers that express these proteins and who are the patients that really might benefit from these exciting new therapies. And of course, there was some data out there, but sort of less than one would imagine in terms of, you know, neuroendocrine carcinomas can really come from anywhere in the body. And so when you're seeing a patient with small cell of the cervix, for example, like what are the chances that their cancer expresses DLL3 or expresses SEZ6? So it was really derived from this pragmatic, clinically oriented question that we had both found ourselves thinking about, and we were lucky enough at MSK, we had started systematically staining patients' tumors for DLL3, tumors that are high-grade neuroendocrine carcinomas, and then we had also more recently started staining for SEZ6 as well. And so we had this nice prospectively collected dataset with which to answer this question. Dr. Rafeh Naqash: Excellent. And Alissa, could you try to go into some of the details around which patients you chose, how many patients, what was the approach that you selected to collect the data for this project? Dr. Alissa Cooper: This is perhaps a strength but also maybe a limitation of this dataset is, as Jesse alluded to, our pathology colleagues are really the stars of this paper here because we were lucky enough at MSK that they were really forethinking. They are absolute experts in the field and really forward-thinking people in terms of what information might be needed in the future to drive treatment decision-making. And so, as Jesse had said, small cell lung cancer tumor samples reflexively are stained for DLL3 and SEZ6 at MSK if there's enough tumor tissue. The other high-grade neuroendocrine carcinomas, those stains are performed upon physician request. And so that is a bit of a mixed bag in terms of the tumor samples we were able to include in this dataset because, you know, upon physician request depends on a number of factors, but actually at MSK, a number of physicians were requesting these stains to be done on their patients with high-grade neuroendocrine cancers of of other histologies. So we looked at all tumor samples with a diagnosis of high-grade neuroendocrine carcinoma of any histology that were stained for these two stains of interest. You know, I can let Jesse talk a bit more about the methodology. She was really the driver of this project. Dr. Jessica Ross: Yeah, sure. So we had 124 tumor samples total. All of those were stained for DLL3, and then a little less than half, 53, were stained for SEZ6. As Alissa said, they were from any primary site. So about half of them were of lung origin, that was the most common primary site, but we included GI tract, head and neck, GU, GYN, even a few tumors of unknown origin. And again, that's because I think a lot of these trials are basket trials that are including different high-grade neuroendocrine carcinomas no matter the primary site. And so we really felt like it was important to be more comprehensive and inclusive in this study. And then, methodologically, we also defined positivity in terms of staining of these two proteins as anything greater than or equal to 1% staining. There's really not a defined consensus of positivity when it comes to these two novel targets and staining for these two proteins. But in the Tarlatamab trials, for some of the correlative work that's been done, they use that 1% cutoff, and we just felt like being consistent with that and also using a sort of more pragmatic yes/no cutoff would be more helpful for this analysis. Dr. Alissa Cooper: And that was a point of discussion, actually. We had contemplated multiple different schemas, actually, for how to define thresholds of positivity. And I know you brought up that question before, what does it mean to be DLL3 positive or DLL3 high? I think you were alluding to prior that there was a presentation of obrixtamig looking at extra-pulmonary neuroendocrine carcinomas, and they actually divvied up the results between DLL3 50% or greater versus DLL3 low under 50%. And they actually did demonstrate differential efficacy certainly, but also some differential safety as well, which is very provocative and that kind of analysis has not been presented for other novel therapies as far as I'm aware. I could be wrong, but as far as I'm aware, that was sort of the first time that we saw a systematic presentation of considering patients to be, quote unquote, "high" or "low" in these sort of novel targets. I think it is important because the label for Tarlatamab does not require any DLL3 expression at all, actually. So it's not hinging upon DLL3 expression. They depend on the fact that the vast majority of small cell lung cancer tumors do express DLL3, 85% to 90% is what's been demonstrated in a few studies. And so, there's not prerequisite testing needed in that regard, but maybe for these extra-pulmonary, other histology neuroendocrine carcinomas, maybe it does matter to some degree. Dr. Rafeh Naqash: Definitely agree that this evolving landscape of trying to understand whether an expression for something actually really does correlate with, whether it's an immune cell engager or an antibody-drug conjugate is a very evolving and dynamically moving space. And one of the questions that I was discussing with one of my friends was whether IHC positivity and the level of IHC positivity, as you've shown in one of those plots where you have double positive here on the right upper corner, you have the double negative towards the left lower, whether that somehow determines mRNA expression for DLL3. Obviously, that was not the question here that you were looking at, but it does kind of bring into question certain other aspects of correlations, expression versus IHC. Now going to the figures in this manuscript, very nicely done figures, very easy to understand because I've done the podcast for quite a bit now, and usually what I try to do first is go through the figures before I read the text, and and a lot of times it's hard to understand the figures without reading the text, but in your case, specifically the figures were very, very well done. Could you give us an overview, a quick overview of some of the important results, Jessica, as far as what you've highlighted in the manuscript? Dr. Jessica Ross: Sure. So I think the key takeaway is that, of the tumors in our cohort, the majority were positive for DLL3 and positive for SEZ6. So about 80% of them were positive for DLL3 and 80% were positive for SEZ6. About half of the tumors were stained for both proteins, and about 65% of those were positive as well. So I think if there's sort of one major takeaway, it's that when you're seeing a patient with a high-grade neuroendocrine carcinoma, the odds are that their tumor will express both of these proteins. And so that can sort of get your head thinking about what therapies they might be eligible for. And then we also did an analysis of some populations of interest. So for example, we know that non-neuroendocrine pathologies can transform into neuroendocrine tumors. And so we specifically looked at that subset of patients with transformed tumors, and those were also- the majority of them were positive, about three-quarters of them were positive for both of these two proteins. We looked at patients with brain met samples, again, about 70% were positive. And then I'd say the last sort of population of interest was we had a subset of 10 patients who had serial biopsies stained for either DLL3 or SEZ6 or both. In between the two samples, these patients were treated with chemotherapy. They were not treated with targeted therapy, but interestingly, in the majority of cases, the testing results were concordant, meaning if it was DLL3 positive to begin with, it tended to remain DLL3 positive after treatment. And so I think that's important as well as we think about, you know, a patient who maybe had DLL3 testing done before they received their induction chemo-IO, we can somewhat confidently say that they're probably still DLL3 positive after that treatment. And then finally, we did do a survival analysis among specifically the patients with lung neuroendocrine carcinomas. We looked at whether DLL3 expression affected progression-free survival on first-line platinum-etoposide, and then we looked at did it affect overall survival. And we found that it did not have an impact or the median progression-free survival was similar whether you were DLL3 positive or negative. But interestingly, with overall survival, we found that DLL3 positivity actually correlated with slightly improved overall survival. These were small numbers, and so, you know, I think we have to interpret this with caution, for sure, but it is interesting. I think there may be something to the fact that five of the patients who were DLL3 positive were treated with DLL3-targeting treatments. And so this made me think of, like in the breast cancer world, for example, if you have a patient with HER2-positive disease, it initially portended worse prognosis, more aggressive disease biology, but on the other hand, it opens the door for targeted treatments that actually now, at least with HER2-positive breast cancer, are associated with improved outcomes. And so I think that's one finding of interest as well. Dr. Rafeh Naqash: Definitely proof-of-concept findings here that you guys have in the manuscript. Alissa, if I may ask you, what is the next important step for a project like this in your mind? Dr. Alissa Cooper: Jesse has highlighted a couple of key findings that we hope to move forward with future investigative studies, not necessarily in a real-world setting, but maybe even in clinical trial settings or in collaboration with sponsors. Are these biomarkers predictive? Are they prognostic? You know, those are still- we have some nascent data, data has been brewing, but I think that we we still don't have the answers to those open questions, which I think are critically important for determining not only clinical treatment decision-making, but also our ability to understand sequencing of therapies, prioritization of therapies. I think a prospective, forward-looking project, piggybacking on that paired biopsy, you know, we had a very small subset of patients with paired biopsies, but a larger subset or cohort looking at paired biopsies where we can see is there evolution of these IHC expression, even mRNA expression, as you're saying, is there differential there? Are there selection pressures to targeted therapies? Is there upregulation or downregulation of targets in response not just to chemotherapy, but for example, for other sort of ADCs or bi-specific T-cell engagers? I think those are going to be critically important future studies which are going to be a bit challenging to do, but really important to figure out this key clinical question of sequencing, which we're all contemplating in our clinics day in and day out. If you have a patient, and these patients often can be sick quite quickly, they might have one shot of what's the next treatment that you're going to pick. We can't guarantee that every patient is going to get to see every therapy. How can you help to sort of answer the question of like what should you offer? So I think that's the key question sort of underlying any future work is how predictive or prognostic are these biomarkers? What translational or correlative studies can we do on the tissue to understand clinical treatment decision-making? I think those are the key things that will unfold in the next couple of years. Dr. Rafeh Naqash: The last question for you, Alissa, that I have is, you are fairly early in your career, and you've accomplished quite a lot. One of the most important things that comes out from this manuscript is your mentorship for somebody who is a fellow and who led this project. For other junior investigators, early-career investigators, how did you do this? How did you manage to do this, and how did you mentor Jessica on this project with some of the lessons that you learned along the way, the good and other things that would perhaps help other listeners as they try to mentor residents, trainees, which is one of the important things of what we do in our daily routine? Dr. Alissa Cooper: I appreciate you calling me accomplished. Um, I'm not sure how true that is, but I appreciate that. I didn't have to do a whole lot with this project because Jesse is an extraordinarily smart, driven, talented fellow who came up with a lot of the clinical questions and a lot of the research questions as well. And so this project was definitely a collaborative project on both of our ends. But I think what was helpful from both of our perspectives is from my perspective, I could kind of see that this was a gap in the literature that really, I think, from my work leading clinical trials and from treating patients with these kinds of cancers that I really hoped to answer. And so when I came to Jessica with this idea as sort of a project to complete, she was very eager to take it and run with it and also make it her own. You know, in terms of early mentorship, I have to admit this was the first project that I mentored, so it was a great learning experience for me as well because as an early-career clinician and researcher, you're used to having someone else looking over your shoulder to tell you, "Yes, this is a good journal target, here's what we can anticipate reviewers are going to say, here are other key collaborators we should include." Those kind of things about a project that don't always occur to you as you're sort of first starting out. And so all of that experience for me to be identifying those more upper-level management sort of questions was a really good learning experience for me. And of course, I was fantastically lucky to have a partner in Jesse, who is just a rising star. Dr. Jessica Ross: Thank you. Dr. Rafeh Naqash: Well, excellent. It sounds like the first of many other mentorship opportunities to come for you, Alissa. And Jessica, congratulations on your next step of joining and being faculty, hopefully, where you're training. Thank you again, both of you. This was very insightful. I definitely learned a lot after I reviewed the manuscript and read the manuscript. Hopefully, our listeners will feel the same. Perhaps we'll have more of your work being published in JCO PO subsequently. Dr. Alissa Cooper: Hope so. Thank you very much for the opportunity to chat today. Dr. Jessica Ross: Yes, thank you. This was great. Dr. Rafeh Naqash: Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe so as you never miss an episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Disclosures: Dr. Alissa Jamie Cooper Honoraria Company: MJH Life Scienes, Ideology Health, Intellisphere LLC, MedStar Health, Physician's Education Resource, LLC,  Gilead Sciences, Regeneron, Daiichi Sankyo/Astra Zeneca, Novartis,  Research Funding: Merck, Roche, Monte Rosa Therapeutics, Abbvie, Amgen, Daiichi Sankyo/Astra Zeneca Travel, Accommodations, Expenses: Gilead Sciences

El calentamiento global está derritiendo el hielo que cubre el océano Ártico, y eso significa que se abre una nueva ruta marítima comercial que acorta considerablemente las distancias entre regiones hasta ahora remotas. Ese deshielo también facilita la explotación de todos los recursos minerales intactos que alberga esta zona del mundo, convertida ya en el escenario de una competición geoestratégica a pesar de que con ello aceleremos la catástrofe climática del planeta. Con Raul Rejón, periodista de elDiario.es especializado en cambio climático, y con Óscar Gelis, colaborador de elDiario.es en Dinamarca, analizamos en qué consiste esta carrera de la codicia por los recursos naturales de una zona fundamental para el clima y el papel que desempeñan los países protagonistas en esta competición. *** Envíanos una nota de voz por Whatsapp contándonos alguna historia que conozcas o algún sonido que tengas cerca y que te llame la atención. Lo importante es que sea algo que tenga que ver contigo. Guárdanos en la agenda como “Un tema Al día”. El número es el 699 518 743See omnystudio.com/listener for privacy information.

Guðrún Hannesdóttir fæddist þann 18. júní árið 1944 og fagnaði því áttræðisafmæli sínu í fyrra. Hún nam listasögu í Lundi og síðar bókasafnsfræði við Háskóla Íslands, starfaði lengst af sem bókasafnsfræðingur og hafði meðal annars umsjón með bókasafni Myndlistarskólans í Reykjavík. Fyrsta ljóðabók Guðrúnar, Fléttur, kom út árið 2007, og sama ár hlaut hún Ljóðstaf Jóns úr Vör. Síðan hefur Guðrún gefið út 9 ljóðabækur til viðbótar, og nú í haust kom út hjá Dimmu eigulegt heildarsafn sem hefur að geyma fyrstu tíu ljóðabækur Guðrúnar. Guðrún skipaði sér seint á skáldabekk en segist kannski alltaf hafa hugsað á þá vegu, hún er lítillát en orð hennar vega þungt, skáldskapurinn djúpur og kjarnyrtur, tungutakið meitlað og myndmálið ríkulegt. Í ljóðum hennar birtist undrun og sannfæring um fegurð hins innsta kjarna og heilagleika náttúrunnar. Guðrún Hannesdóttir, skáld, er gestur svipmyndar í dag.

Aquesta setmana Pere Becque analitza la situació judicial i política dels polítics catalans exiliats i presos en relació amb el procés independentista i la llei d'amnistia aprovada recentment a l'estat espanyol. Tot i que aquesta llei ja ha estat aplicada a cossos com la Guàrdia Civil, encara està pendent la seva aplicació als polítics catalans.

Svavar Jónatansson vinnur við prufuverkefni hjá Hrafnistu þar sem hann hefur nýtt sér tækni sýndarveruleika til þess að færa heimilisfólkinu á Hrafnistu í aðstæður sem þau ættu annars erfitt með að komast í. Hann sem sagt fer með 360° myndavél á kóræfingu og svo getur heimilisfólk sett á sig sérstök sýndarveruleikagleraugu, eða töfragleraugu eins og hann kallar þau, og þá eru þau nánast komin á staðinn og geta jafnvel sungið með í kórnum. Möguleikarnir eru óendanlegir í því hvernig hægt er að nýta þessa tækni og Svavar útskýrði betur fyrir okkur hvernig þetta gengur fyrir sig. Að jóðla er ákveðin söngkúnst og ekki á allra færi en nú stendur til að halda jóðlkeppni, nánar tiltekið í desember, Jóðlageitina 2025. Bragi Þór Valsson tónlistarmaður kom í þáttinn og sagði okkur frá jóðli og keppninni í dag. Svo fræddumst við um Textílmiðstöð Íslands á Blönduósi, en þar verður viðburður í dag sem kallast Saman við sitjum og saumum inni í stóru húsi. Þar munu fatahönnunarnemendur í Listaháskólanum bjóða til vinnustofu og sýna áhugaverð dæmi og aðstoða þáttakendur við að breyta, bæta og jafnvel skapa nýja flíkur úr gömlum. Elsa Arnardóttir forstöðumaður Textílmiðstöðvar sagði okkur betur frá þessu í þættinum í dag. Tónlist í þættinum i dag: Lítið og væmið / Valdimar (Valdimar Guðmundsson) Hærra minn guð / Kór Lindarkirkju (Lowell Mason, texti Matthías Jochumsson) Yodel-blús / Smaladrengirnir (Bragi Þór Valsson) Reiðlag / Þuríður Sigurðardóttir (S. Bogus, texti Jónas Friðrik Guðnason) UMSJÓN: GUÐRÚN GUNNARSDÓTTIR OG GUNNAR HANSSON

Qui va appeler RMC aujourd'hui ? Tom Cruise, Emmanuel Macron ? Gislain de Guéret ? « Le répondeur de Pierre-Antoine Damecour » détourne le 3216 de RMC tous les jours, du lundi au vendredi, à 13h50 dans « Estelle Midi ».

00:00:00 : Bande-annonce Conférence Guérison & Réveil 2e édition 00:01:37 : Début de l'émission

La realidad no es lo que crees. No estás observando el mundo: estás proyectándolo. Este análisis del libro El Universo Holográfico de Michael Talbot explica por qué tu mente construye la realidad que llamas “yo” y cómo puedes cambiarla sin luchar contra ella. Aquí no vas a encontrar teoría superficial ni misticismo diluido. Vamos a lo esencial: Cómo se genera tu experiencia, cómo operas tu identidad y cómo puedes cambiar tu realidad desde adentro. LO QUE VAS A ENTENDER: - Por qué tu cerebro funciona como un holograma. - Cómo la realidad se proyecta desde tu percepción. - La conexión entre mente, cuerpo y tiempo. - El error que te mantiene re-creando el mismo “yo”. - Y cómo cambiar tu proyección sin pelear con la realidad. META DE LA COMUNIDAD: Si este video llega a: ✅ 2,000 Me gusta ✅ 800 Comentarios Liberaré un Contenido Especial: Los 7 pasos prácticos para cambiar tu proyección interna sin entrar en lucha con tu realidad. Para participar, comenta: "Quiero ver lo que no estoy viendo." SI NO QUIERES ESPERAR: Reto 7D | Recupera tu Centro de Poder https://recursos.conocimientoexperto.com/reto7dias3f SÍGUEME: Web: https://conocimientoexperto.com YouTube: https://www.youtube.com/@conocimientoexperto Podcast: https://open.spotify.com/show/65J8RTsruRXBxeQElVmU0b Instagram: https://www.instagram.com/salvadormingo/ LinkedIn: https://www.linkedin.com/in/salvadormingoce/ Guías prácticas: https://conocimientoexperto.com/accede-a-las-guias Salvador Mingo Creador de Conocimiento Experto | Estratega en desarrollo personal y enfoque interno Autor de Mentalidad con Propósito y La Estrategia Maestra +50 millones de impactos en plataformas digitales salvador@conocimientoexperto.com #ElUniversoHolográfico #MichaelTalbot #dominiointerno #conocimientoexperto #cambiointerno

La realidad no es lo que crees. No estás observando el mundo: estás proyectándolo. Este análisis del libro El Universo Holográfico de Michael Talbot explica por qué tu mente construye la realidad que llamas “yo” y cómo puedes cambiarla sin luchar contra ella. Aquí no vas a encontrar teoría superficial ni misticismo diluido. Vamos a lo esencial: Cómo se genera tu experiencia, cómo operas tu identidad y cómo puedes cambiar tu realidad desde adentro. LO QUE VAS A ENTENDER: - Por qué tu cerebro funciona como un holograma. - Cómo la realidad se proyecta desde tu percepción. - La conexión entre mente, cuerpo y tiempo. - El error que te mantiene re-creando el mismo “yo”. - Y cómo cambiar tu proyección sin pelear con la realidad. META DE LA COMUNIDAD: Si este video llega a: ✅ 2,000 Me gusta ✅ 800 Comentarios Liberaré un Contenido Especial: Los 7 pasos prácticos para cambiar tu proyección interna sin entrar en lucha con tu realidad. Para participar, comenta: "Quiero ver lo que no estoy viendo." SI NO QUIERES ESPERAR: Reto 7D | Recupera tu Centro de Poder https://recursos.conocimientoexperto.com/reto7dias3f SÍGUEME: Web: https://conocimientoexperto.com YouTube: https://www.youtube.com/@conocimientoexperto Podcast: https://open.spotify.com/show/65J8RTsruRXBxeQElVmU0b Instagram: https://www.instagram.com/salvadormingo/ LinkedIn: https://www.linkedin.com/in/salvadormingoce/ Guías prácticas: https://conocimientoexperto.com/accede-a-las-guias Salvador Mingo Creador de Conocimiento Experto | Estratega en desarrollo personal y enfoque interno Autor de Mentalidad con Propósito y La Estrategia Maestra +50 millones de impactos en plataformas digitales salvador@conocimientoexperto.com #ElUniversoHolográfico #MichaelTalbot #dominiointerno #conocimientoexperto #cambiointernoConviértete en un seguidor de este podcast: https://www.spreaker.com/podcast/conocimiento-experto--2975003/support.

====================================================https://www.youtube.com/channel/UCNpffyr-7_zP1x1lS89ByaQ?sub_confirmation=1====================================================DEVOCIÓN MATUTINA PARA JOVENCITAS“PRINCESA”Narrado por: Sirley DelgadilloDesde: Bucaramanga, ColombiaUna cortesía de DR'Ministries y Canaan Seventh-Day Adventist Church===================|| www.drministries.org ||===================19 DE NOVIEMBRENO SEAMOS NECIAS El que confía en su propio corazón es necio; Mas el que camina en sabiduría será librado. Proverbios 28:26 ¿Alguna vez escuchaste una de estas líneas? “Sigue a tu corazón.” “¿Qué te está diciendo tu corazón?” “Deja que tu corazón sea tu Guía.” El mundo de hoy da un mensaje claro para buscar dirección en nuestros propios corazones. Pero, ¿son nuestros corazones la mejor guía para tomar decisiones importantes en la vida? La Biblia dice que no se puede confiar en nuestro corazón. De hecho, Dios nos llama necios cuando confiamos en nuestro propio corazón. Esas son palabras poderosas y fuertes. Piénselo: es posible que deseemos tan profundamente un compañero para compartir las alegrías y los desafíos de la vida que permitimos que nuestros sentimientos desesperados nos lleven a tomar decisiones apresuradas, decisiones de las que luego podamos arrepentirnos. Nuestro corazón podría persuadirnos de racionalizar: “Será un buen proveedor; solo necesita ayuda para encontrar un trabajo”. O peor aún, “Realmente es cristiano, simplemente no le gusta la iglesia”. Tomar decisiones basadas en las inclinaciones del corazón puede llevarnos a un mundo de problemas, incluso peligro. Aunque los sentimientos son importantes, nunca deben ser la única base de una elección que hagamos. No seamos necias. 

¿Tu podcast no crece como esperabas? En este episodio comparto los errores más comunes que pueden estar deteniendo el crecimiento de tu audiencia y cómo corregirlos con intención y estrategia.GRATIS Descarga mi Guía de YouTube para Podcasters aquí: https://www.focusandbloomstudios.com/guia-de-youtube-para-podcasters//////////////////////////////////////////////////Ahorra tiempo en la producción de tu podcast con el Complete Podcast Bundle https://www.focusandbloomstudios.com/podcastbundle-espanol

Carlos Mazón ha comparecido en dos comisiones parlamentarias de investigación en dos semanas. Una, en les Corts Valencianes. Otra, en el Congreso de los diputados. En las dos ha echado balones fuera… él no pudo haber hecho más de lo que hizo. Escuchar a Mazón decir que él no tenía responsabilidad en el envío del es-Alert o que nada habría cambiado si hubiera estado en el CECOPI… Nos ha llevado a Ayuso, a aquel momento en el que, aunque no lo dijo literalmente, transmitió la idea de que las personas mayores de las residencias, en la pandemia, se habrían muerto de igual manera. Repasamos la declaración de Carlos Mazón, sus mentiras y lo más llamativo de lo que ha dicho en la comisión de investigación con la periodista de elDiario.es, Raquel Ejerique. *** Envíanos una nota de voz por Whatsapp contándonos alguna historia que conozcas o algún sonido que tengas cerca y que te llame la atención. Lo importante es que sea algo que tenga que ver contigo. Guárdanos en la agenda como “Un tema Al día”. El número es el 699 518 743See omnystudio.com/listener for privacy information.

Á dögunum kom út fjórða breiðskífa spænsku tónlistarkonunnar Rosalia. 14 tungumál, sinfóníuhljómsveit, tólftu aldar nunna, óperusöngur, flamengó og Björk koma öll við sögu. Með plötunni LUX er Rosalia að stimpla sig rækilega inn sem einhvern merkilegasta popptónlistarmann samtímans. Friðrik Margrétar Guðmundsson mætir í Lestina til að kryfja til mergjar versta lag plötunnar (að mati Friðriks), fyrstu smáskífuna, Berghain. Við flettum svo í glænýrri íslenskri myndasögu, Larfur Lauks: lifandi og deyandi í Reykjavík. Myndasagan rekur ævintýri Larfs og vinahóps hans, sem er fjölskrúðugur hópur furðufugla og djammara. Einn þeirra er brauðsneið, enn er skjaldbaka sem selur hass og spilar Counter strike, sá þriðji missir óvart typpið í skyndikynnum á klósettinu á skemmtistað. Mennirnir á bakvið söguna eru teiknarinn og myndlistarmaðurinn Björn Heimir Önundarson og Tumi Björnsson, sem hefur gert garðinn frægan með myndböndum og stuttmyndum undir merkjum Kaupa Dót.

Öll viðtölin úr þætti dagsins ásamt símatíma: Guðni Sigurðsson upplýsingafulltrúi Icelandair Sigurður Hannesson framkvæmdastjóri Samtaka iðnaðarins um verndartolla ESB Þorgerður Katrín Gunnarsdóttir utanríkisráðherra um verndartolla ESB Símatími Steinunn Þórðardóttir öldrunarlæknir og formaður Læknafélags Íslands um rannsókn frá Ástralíu um að yngra fólk en áður er að greinast með minnisglöp líklega vegna samfélagsmiðla og skjánotkunar Stefán Einar Stefánsson um myndband sem er í dreifingu á Tik Tok Sigmundur Davíð Gunnlaugsson formaður Miðslokksins um verndartolla ESB Lára Zulima Ómarsdóttir fyrrverandi fréttamaður og almannatengill um frétta-sjónvarpsstöðina NFS sem fór í loftið fyrir 20 árum Skúli Bragi Geirdal varaþingmaður Framsóknarflokksins og sviðsstjóri hjá Netvís netöryggismiðstöðvarinnar um netöryggi barna

Conversem amb el ministre de Drets Socials, Consum i Agenda 2030, Pablo Bustinduy, el dia que s'ha sabut un nou informe de la Gu

Qui va appeler RMC aujourd'hui ? Tom Cruise, Emmanuel Macron ? Gislain de Guéret ? « Le répondeur de Pierre-Antoine Damecour » détourne le 3216 de RMC tous les jours, du lundi au vendredi, à 13h50 dans « Estelle Midi ».

My guest on today's episode of Nudge has spent decades studying leaders.  I asked Prof. Adam Galinsky to share his top five (evidence-backed) leadership tips.  Want to become a better leader?  This is the episode for you.  ---  Watch the bonus episode: https://nudge.kit.com/a53ff22931  Read Adam's book: https://amzn.to/4htZCGc Sign up for my newsletter: https://www.nudgepodcast.com/mailing-list Connect on LinkedIn: https://www.linkedin.com/in/phill-agnew-22213187/ Watch Nudge on YouTube: https://www.youtube.com/@nudgepodcast/ --- Blunden, H., Kristal, A. S., Whillans, A. V., Yoon, J., Burd, K., Bremner, S., & Yeomans, M. (2025). Eliciting advice instead of feedback improves developmental input. Organizational Behavior and Human Decision Processes, 193, 104343. Chou, E. Y., Halevy, N., Galinsky, A. D., & Murnighan, J. K. (2017). The Goldilocks contract: The synergistic benefits of combining structure and autonomy for persistence, creativity, and cooperation. Journal of Personality and Social Psychology, 113(3), 393–412. Hoff, M., Rucker, D. D., & Galinsky, A. D. (2025). The vicious cycle of status insecurity. Journal of Personality and Social Psychology, 128(1), 101–122. Leonardelli, G. J., Gu, J., McRuer, G., Medvec, V. H., & Galinsky, A. D. (2019). Multiple equivalent simultaneous offers (MESOs) reduce the negotiator dilemma: How a choice of first offers increases economic and relational outcomes. Organizational Behavior and Human Decision Processes, 152, 64–82. Liljenquist, K. A., & Galinsky, A. D. (2007). Turn your adversary into your advocate: Strategic requests for advice can transform disputes into amiable problem-solving ventures. Kellogg Insight. Northwestern University. Majer, J. M., Trötschel, R., Galinsky, A. D., & Loschelder, D. D. (2020). Open to offers, but resisting requests: How the framing of anchors affects motivation and negotiated outcomes. Journal of Personality and Social Psychology, 119(3), 582–599. Wu, S. J., & Paluck, E. L. (2022). Having a voice in your group: Increasing productivity through group participation. Behavioural Public Policy, 9(1), 192–211.

00:00:00 : Bande-annonce Conférence Guérison & Réveil 2e édition 00:01:37 : Début de l'émission

La segunda quincena de noviembre trae los tránsitos astrológicos más transformadores del 2025. Con la Luna Nueva en Escorpio del 20 de noviembre y el Gran Trígono de Agua más potente del año, es tu oportunidad de hacer un corte definitivo con el pasado antes de entrar a la energía de libertad total que nos espera en 2026.En este video de astrología psicológica descubrirás cómo estos tránsitos planetarios cierran el ciclo que comenzó en septiembre con los eclipses, y por qué este período es perfecto para limpiar memorias inconscientes y patrones familiares.Guía Astrológica 2026 GRATUITA – Descubre mes a mes los movimientos planetarios y cómo alinearte con ellos → https://bit.ly/guia-astrologica-2026

El presidente del Gobierno en Radio 3. Vestido con una camiseta negra, una cazadora negra, en un tono distendido y cercano, justo en el momento en el que en el Tribunal Supremo decían “visto para sentencia” en el juicio al fiscal general del Estado… Pedro Sánchez se fue a Radio 3, la emisora musical de Radio Nacional de España. ¿A qué? A hablar de lo que todo el mundo habla: de Rosalía. Pero en ese gesto, se esconden muchas más cosas. Muchas personas han comparado esta visita a la radio pública con la que Sánchez hizo al podcast ‘La pija y la quinqui’. Eso fue en 2023, en la campaña electoral del 23J. ¿Significa eso que Pedro Sánchez va a convocar elecciones anticipadas? Lo abordamos con los periodistas de elDiario.es José Enrique Monrosi e Irene Castro y con el consultor político y director de Cámara Cívica, Manu Rodríguez. *** Envíanos una nota de voz por Whatsapp contándonos alguna historia que conozcas o algún sonido que tengas cerca y que te llame la atención. Lo importante es que sea algo que tenga que ver contigo. Guárdanos en la agenda como “Un tema Al día”. El número es el 699 518 743See omnystudio.com/listener for privacy information.

Öll viðtölin úr þætti dagsins ásamt símatíma: Læknaneminn Margrét Sól Torfadóttir keppir til úrslita í dönsku bakarakeppninni Den store bagedyst Stóra Bakaraslagnum. Magnús Árni Skjöld Magnússon formaður Evrópuhreyfingarinnar um verndartolla Evrópusambandsins á kísilmálmi og Hjörtur Guðmundsson sagnfræðingur og alþjóðastjórnmálafræðingur með síðuna stjornmalin.is Símatími Guðrún Aspelund sóttvarnalæknir um Inflúensu sem leikur landann grátt Ólafur Margeirssson hagfræðingur um vexti og gjaldmiððilinn Bryndís Loftsdóttir hjá félagi bókaútgefenda um bókajólin 2025 Sævar Helgi Bragason Stjörnu Sævar vísindamiðlar um sólstorma og Carrington Event sem varð 1859 Gunnar Dan um geimverur, fljúgandi furðuhluti og sögu samskipta mannkyns við ójarðneskar verur

Simulación vs. realidad. ¿Y si tu vida fuera un juego diseñado por otros seres para que recuerdes quién eres en verdad? Ricky Angulo revela cómo despertar de la “simulación” que llamamos realidad y hackear tu mente emocional. Descubre cómo tus emociones programan tu entorno y cómo recuperar el control de tu vida, transformando miedo y caos en poder. Sal del avatar y conviértete en un CREADOR CONSCIENTE. Guía clara con ciencia, simbolismo y ejercicios simples para salir de la Matrix. Ricky Angulo Graduado en PNL con certificación de Coach Internacional. Especializado en Reiki Tibetano, Cirugía Astral Bioquantum, Psicoterapia Transpersonal, Biodescodificación y lectura de tarot. Más información en: https://www.mindaliatelevision.com PARTICIPA CON TUS COMENTARIOS EN ESTE VÍDEO. ------------ INFORMACIÓN SOBRE MINDALIA ---------- Mindalia.com es una ONG internacional, sin ánimo de lucro, que difunde universalmente contenidos sobre espiritualidad y bienestar para la mejora de la consciencia del mundo. Apóyanos con tu donación en: https://www.mindalia.com/donar/ - Suscríbete, comenta positivamente y comparte nuestros vídeos para difundir este conocimiento a miles de personas. Nuestro sitio web: https://www.mindalia.com SÍGUENOS TAMBIÉN EN NUESTRAS PLATAFORMAS https://www.mindalia.com/plataformas/ *Mindalia.com no se hace responsable de las opiniones vertidas en este vídeo, ni necesariamente participa de ellas. #Matrix #Simulación #Hackeo

Dimitri and Khalid explore the life and philosophy of early 20th century French esotericist René Guénon, including: Guénon's philosophy of "Traditionalism", how it overlaps with and differs from "Perennialism", his mostly solid criticisms of Theosophy as a sus pseudo-tradition, his influence on the Italian fascist mystic Julius Evola, Guénon's (partially) salient critiques of "rationalism", capitalism, and the spiritual void of Western Civilization, intriguing overlaps between Marxist and Traditionalist critiques of modernity, his later embrace of Sufism and quasi-Third Worldist tendencies, the Guenonist-inspired thought of His Majesty King Charles, and more... For access to full-length premium SJ episodes, upcoming installments of DEMON FORCES, and the Grotto of Truth Discord, subscribe at https://patreon.com/subliminaljihad.

Tras más de 20 años de experiencia en el mundo espiritual, Cristina Acebrón comparte cómo los mensajes de sus Guías han sido clave para tomar decisiones y vivir con mayor consciencia. Los Guías Espirituales son una parte esencial en el camino de toda persona que elige la Espiritualidad como forma de vida. Aprende a sentir, escuchar e interpretar los mensajes de tus Guías para avanzar en tu evolución espiritual, desde el amor incondicional y la luz interior. Cristina Acebrón Transmite mensajes espirituales para ayudar a la Humanidad. Canaliza las enseñanzas del Grupo de los 9, que son Conciencias elevadas que conectan con las necesidades del ser humano actual. https://www.cristinaacebronguirau.com/terapias/ https://www.cristinaacebronguirau.com/ https://www.instagram.com/cristinaacebronguirau/ https://www.facebook.com/CristinaAcebronGuirau Más información en: https://www.mindaliatelevision.com PARTICIPA CON TUS COMENTARIOS EN ESTE VÍDEO. ------------ INFORMACIÓN SOBRE MINDALIA ----------DPM Mindalia.com es una ONG internacional, sin ánimo de lucro, que difunde universalmente contenidos sobre espiritualidad y bienestar para la mejora de la consciencia del mundo. Apóyanos con tu donación en: https://www.mindalia.com/donar/ - Suscríbete, comenta positivamente y comparte nuestros vídeos para difundir este conocimiento a miles de personas. Nuestro sitio web: https://www.mindalia.com SÍGUENOS TAMBIÉN EN NUESTRAS PLATAFORMAS https://www.mindalia.com/plataformas/ *Mindalia.com no se hace responsable de las opiniones vertidas en este vídeo, ni necesariamente participa de ellas. #GuíasEspirituales #Conexión #Enseñanzasv

LAUDES SÁBADO DE LA XXXII SEMANA DEL TIEMPO ORDINARIO(Oración de la mañana) - IV Salterio*Link de apoyo al canal al final del escrito*INVOCACIÓN INICIALV. Señor abre mis labiosR. Y mi boca proclamará tu alabanzaINVITATORIOAnt. Escuchemos la voz del Señor y entremos en su descanso.SALMODIASalmo 91 - Ant.Es bueno tocar para tu nombre, oh Altísimo, y proclamar por la mañana tu misericordia.Cántico - Ant. Os daré un corazón nuevo y os infundiré un espíritu nuevo.Salmo 8 - Ant. De la boca de los niños de pecho, Señor, has sacado una alabanzaCÁNTICO EVANGÉLICOAnt. Guía nuestros pasos, Dios de Israel, por el camino de la paz.Cántico de Zacarías. EL MESÍAS Y SU PRECURSOR      Lc 1, 68-79Bendito sea el Señor, Dios de Israel,porque ha visitado y redimido a su pueblo.suscitándonos una fuerza de salvaciónen la casa de David, su siervo,según lo había predicho desde antiguopor boca de sus santos profetas:Es la salvación que nos libra de nuestros enemigosy de la mano de todos los que nos odian;ha realizado así la misericordia que tuvo con nuestros padres,recordando su santa alianzay el juramento que juró a nuestro padre Abraham.Para concedernos que, libres de temor,arrancados de la mano de los enemigos,le sirvamos con santidad y justicia,en su presencia, todos nuestros días.Y a ti, niño, te llamarán Profeta del Altísimo,porque irás delante del Señora preparar sus caminos,anunciando a su pueblo la salvación,el perdón de sus pecados.Por la entrañable misericordia de nuestro Dios,nos visitará el sol que nace de lo alto,para iluminar a los que viven en tinieblay en sombra de muerte,para guiar nuestros pasospor el camino de la paz.Gloria al Padre, y al Hijo, y al Espíritu Santo.Como era en el principio, ahora y siempre, por los siglos de los siglos. Amén.PRECES“Escúchanos, Señor. ”ConclusionV. El Señor nos bendiga, nos guarde de todo mal y nos lleve a la vida eterna.R. Amén.(658)

Get Lifted 246 – Live Melodic House Session | We Get Lifted Radio Welcome to episode 246 of the Get Lifted podcast, recorded live for We Get Lifted Radio. This time I'm switching things up with a melodic house journey — full of emotion, groove, and uplifting energy.It's a little different from my usual soulful and afro house mixes, but still carries that signature Get Lifted feel. Turn it up and let the melodies take you higher.  If you enjoy these sounds, check out my Diggin Deep sessions on Mixcloud!Let's Get Lifted together.— DJ Lady DuracellTracklistSamantha Loveridge - Moon Child (feat. Joel Winterflood) Lost Miracle, Sebastien Leger, Roy Rosenfeld - Closer To You (Extended Mix)Eli & Fur - It Feels Different Now (Extended Mix)Unknowns, X-sylo - The Time Has Come (Original Mix)Nihil Young - Can't Stop Now (Extended Mix)Sandro Beninati, TYGR TYGR, Sihnara - Afterglow (Extended Mix)Sander Wilder - A Part of MeSailor & I, Helsloot - Best of Me (Extended Mix)Jody Vukas - Close To Me (Original Mix)Kryder - Time (Extended Mix)Franky Wah - Take A Flight (Original Mix)Rezident, Kate Morgan - Muse feat. Kate Morgan (L.GU. Extended Mix)https://www.instagram.com/wegetliftedradiohttps://www.instagram.com/djladyduracellhttps://www.tiktok.com/@wegetliftedradiohttps://ladyduracellqueenoffunk.podomatic.comhttps://www.facebook.com/LadyDuracellDJhttps://www.facebook.com/groups/ladyduracellhttps://X.com/wegetlifted_https://X.com/LadyDuracellhttps://www.ladyduracell.comGet Lifted Merch:https://www.JackFresh.com

Curso de Rent to Rent: https://libertadinmobiliaria.es/rent-to-rent-lista-p   ¡Bienvenido al podcast de Libertad Inmobiliaria!

Spadoni and Shasky discuss Brocks return and the magnitude of this game for him. The Roast holds court to assess the 49ers. Steiny and Gu join the show for the crossover!

In today's episode, filmed live at the 43rd Annual Chemotherapy Foundation Symposium, lung cancer expert Benjamin P. Levy, MD, hosted a cross-specialty discussion with genitourinary (GU) cancer expert Scott T. Tagawa, MD, MS, FACP, FASCO, about the rapidly evolving treatment paradigms for prostate and kidney cancer. Dr Levy is the clinical director of medical oncology at the Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital and an associate professor of oncology at the Johns Hopkins University School of Medicine in Washington, DC. Dr Tagawa is a professor of medicine and urology at Weill Cornell Medicine, as well as an attending physician at NewYork-Presbyterian – Weill Cornell Medical Center in New York, New York. Their conversation began with a focus on prostate-specific membrane antigen (PSMA)–positive prostate cancer. Dr Tagawa explained that PSMA is a cell surface protein, and that PSMA imaging agents are commonly used to assess biochemical recurrence and perform initial disease staging. He noted that therapy-related adverse effects are often site-specific, including dry mouth/change in taste, and myelosuppression from the radiation payload. For monitoring long-term safety, Dr Tagawa emphasized that renal function must be tracked. Beyond PSMA, other prostate cancer targets include TROP-2, B7-H3, and markers specific to aggressive or neuroendocrine variants, such as DLL3, he reported. In advanced GU cancers, circulating tumor DNA (ctDNA) testing is increasingly important, Dr Tagawa highlighted. In prostate cancer, ctDNA testing is used to assess homologous recombination deficiency (HRD) status and BRCA expression, he said, explaining that evidence for the use of ctDNA testing in GU cancers stems from findings with this type of assay to evaluate minimal residual disease levels in urothelial cancer. He noted that studies show that if patients with urothelial cancer become ctDNA positive within the first year of receiving neoadjuvant chemotherapy, they benefit from treatment with atezolizumab (Tecentriq). Similarly, he stated that patients with previously untreated HRD-positive metastatic prostate cancer also see a progression-free survival benefit when a PARP inhibitor is added to an androgen deprivation therapy/androgen receptor pathway inhibitor backbone. Shifting the conversation to the management of frontline advanced clear cell renal cell carcinoma (RCC), the experts reviewed standard approaches, which involve an immune-oncology (IO) agent plus either a CTLA-4 inhibitor or a VEGF TKI. Tagawa noted that IO/VEGF TKI combinations may be preferred for symptomatic patients needing a rapid response, whereas IO/IO combinations may offer greater potential for treatment cessation. He brought up a key distinction in RCC, which is that re-instituting PD-1/PD-L1 inhibition upon progression in the metastatic setting has generally shown no benefit. Dr Levy brought a broad scope to the GU cancer discussion through his lung cancer expertise, introducing parallels between the treatment paradigms. The interview provided an opportunity to show the importance of creating connections across oncology specialties to bring nuanced perspectives to future advances in clinical research and patient care.